삼성서울병원

Ko En
의료진 검색
찾으실 의료진명을 입력하여 검색해주세요.

혈액종양내과 정현애 교수

진료분야
폐암, 두경부암, 식도암, 뇌종양
진료일정 05 月
날짜
수
01
목
02
금
03
토
04
일
05
월
06
화
07
수
08
목
09
금
10
토
11
일
12
월
13
화
14
수
15
목
16
금
17
토
18
일
19
월
20
화
21
수
22
목
23
금
24
토
25
일
26
월
27
화
28
수
29
목
30
금
31
오전
오후
진료일정 06 月
날짜
토
01
일
02
월
03
화
04
수
05
목
06
금
07
토
08
일
09
월
10
화
11
수
12
목
13
금
14
토
15
일
16
월
17
화
18
수
19
목
20
금
21
토
22
일
23
월
24
화
25
수
26
목
27
금
28
토
29
일
30
오전
오후
본원외래 본원클리닉 본원육아상담 암병원외래 암병원클리닉 암병원육아상담

학력

학력
2014.08 성균관대학교 의과대학 대학원 졸업 (박사)
2012.02 성균관대학교 의과대학 대학원 졸업 (석사)
2007.02 경북대학교 의과대학 졸업 (학사)

경력

경력
2023.03 ~현재 삼성서울병원 혈액종양내과 부교수
2022.03 ~ 2023.02 삼성서울병원 혈액종양내과 진료부교수
2020.03 ~ 2022.02 삼성서울병원 혈액종양내과 진료조교수
2018.03 ~ 2020.02 삼성서울병원 혈액종양내과 임상조교수
2015.03 ~ 2018.02 한림대학교 동탄성심병원 임상조교수
2013.03 ~ 2015.02 성균관대학교 삼성서울병원 혈액종양내과 임상강사
2008.09 ~ 2012.08 성균관대학교 삼성서울병원 내과 전공의
2007.03 ~ 2008.02 성균관대학교 삼성서울병원 인턴

학회활동

학회활동
International Association for the Study of Lung Cancer 정회원
대한내과학회 정회원
대한암학회 정회원
대한종양내과학회 정회원
대한폐암학회 정회원
대한항암요법연구회 정회원
미국암학회 정회원

수상이력

수상이력
2021.01 대한종양내과학회 학술 연구비상
2019.01 대한폐암학회 추계학술대회 우수 연제상
2017.01 JSH 2017 Travel Award
2017.01 대한항암요법연구회 12th Methodology Workshop 우수 프로토콜 상
2015.01 ESMO ASIA Young Investigator Award
2015.01 JSH 2015 Travel Award
2014.01 대한암학회 로슈 학술상
2014.01 임상암학회 한국암학술재단 학술상
2012.01 한국암학술재단 암 연구 장학생
2011.01 삼성서울병원 내과 전공의 영어 논문 발표 우수상
2011.01 제 1회 젊은 의사 아카데미 유한 학술상
2008.01 삼성서울병원 우수전공의상
논문
  • JAMA NETW OPEN 2024 10.1001/jamanetworkopen.2023.55331 Epidemiology and Outcomes of Non-Small Cell Lung Cancer in South Korea Jung, HA; Lee, DH; Lim, SM; Yu, H; Yoon, S; Kim, D; Kim, KP; Jeong, H; Doh, H; Lim, S; Kim, J; Zhao, XH; Horsburgh, D; Patel, D; Kim, JA; Toh, KC
    View PubMed
  • CANCER RES TREAT 2024 10.4143/crt.2023.461 First-Line Alectinib vs. Brigatinib in Advanced Non-Small Cell Lung Cancer with ALKRearrangement: Real-World Data Jeon, Y; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ
    View PubMed
  • CANCER-AM CANCER SOC 2024 10.1002/cncr.35175 Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune-related hepatitis in non-small cell lung cancer patients with chronic hepatitis B Hong, J; Lee, J; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Sinn, DH; Ahn, MJ
    View PubMed
  • TRANSL LUNG CANCER R 2023 10.21037/tlcr-23-643 Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC) Choi, DH; Jung, HA; Park, S; Sun, JM; Ahn, JS; Ahn, MJ; Lee, SH
    View PubMed
  • CANCERS 2023 10.3390/cancers15225450 Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations Jun, S; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Cho, J; Jung, HA
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2023.502 Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Kim, H; Park, S; Jung, HA; Lee, SH; Park, K; Ahn, YC; Oh, D; Ahn, MJ
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2023.403 Expanded Access Program Pralsetinib in Advanced Non-Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement Jeon, Y; Jung, HA; Park, S; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH
    View PubMed
  • CANCER-AM CANCER SOC 2023 10.1002/cncr.35059 Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer Park, S; Kim, YJ; Min, YJ; Mortimer, PGS; Kim, HJ; Smith, SA; Dean, E; Jung, HA; Sun, JM; Park, WY; Ahn, JS; Ahn, MJ; Lee, SH; Park, K
    View PubMed
  • J THORAC ONCOL 2023 10.1016/j.jtho.2023.05.027 Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung Cancer Jung, HA; Ku, BM; Kim, YJ; Park, S; Sun, JM; Lee, SH; Ahn, JS; Cho, JH; Kim, HK; Choi, YS; Choi, YL; Shin, SH; Jeong, BH; Um, SW; Kim, H; Kim, K; Ahn, MJ; Kim, J
    View PubMed
  • TRANSL LUNG CANCER R 2023 10.21037/tlcr-23-160 Real-world clinical evidence of lazertinib use in acquired EGFR T790M mutated non-small cell lung cancer Park, S; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM
    View PubMed
  • CANCER MED-US 2023 10.1002/cam4.6213 A multicenter, phase II trial of GC1118, a novel anti-EGFR antibody, for recurrent glioblastoma patients with EGFR amplification Choi, SW; Jung, HA; Cho, HJ; Kim, TM; Park, CK; Nam, D; Lee, SH
    View PubMed
  • J THORAC ONCOL 2023 10.1016/j.jtho.2023.03.024 Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced NSCLC Hong, TH; Bang, YH; Joe, CY; Hwang, S; Lee, B; Lee, N; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Choi, YL; Lee, SH
    View PubMed
  • CANCER-AM CANCER SOC 2023 10.1002/cncr.34892 A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas Lee, J; Park, S; Jung, HA; Lee, SH; Seo, S; Kim, SB; Kim, JW; Lee, KW; Kang, EJ; Kim, JW; Choi, YJ; Shim, BY; An, HJ; Park, LC; Shin, SH; Kim, JJ; Oh, SY; Kim, MK; Ahn, MJ
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2022.1344 The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Jung, HA; Park, S; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2022.388 EGFR Mutation-Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis Kim, H; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ
    View PubMed
  • ADV SCI 2023 10.1002/advs.202204378 Intracellular Adhesion Molecule-1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8(+) T Cells Lee, SH; Kim, Y; Jeon, BN; Kim, G; Sohn, J; Yoon, Y; Kim, S; Kim, Y; Kim, H; Cha, HG; Lee, NE; Yang, HYS; Chung, JY; Jeong, AR; Kim, YY; Kim, SG; Seo, Y; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, H; Yoon, KW
    View PubMed
  • JAMA NETW OPEN 2023 10.1001/jamanetworkopen.2023.2002 Trends in Survival Rates of Non-Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020 Chi, SA; Yu, H; Choi, YL; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Choi, DH; Kim, K; Jung, HA; Park, K
    View PubMed
  • CLIN CANCER RES 2023 10.1158/1078-0432.CCR-22-3549 Clinicopathologic and Molecular Subtyping of EGFR Mutation-Response Jung, HA; Lim, J; Choi, YL; Kim, J; Park, K
    View PubMed
  • J IMMUNOTHER CANCER 2023 10.1136/jitc-2022-005509 Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment Kim, H; Park, S; Han, KY; Lee, N; Kim, H; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Lee, SH; Park, WY
    View PubMed
  • J THORAC ONCOL 2023 10.1016/j.jtho.2022.10.008 A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21) Jung, HA; Kim, M; Kim, HS; Kim, JH; Choi, YH; Cho, J; Park, JH; Park, KU; Ku, BM; Park, S; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2021.1603 Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non-Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI Kim, HR; Jo, H; Kim, H; Hong, J; Park, S; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ
    View PubMed
  • INT J RADIAT ONCOL 2023 10.1016/j.ijrobp.2022.07.018 Association of T Cell Senescence with Radiation Pneumonitis in Patients with Non-small Cell Lung Cancer Kim, KH; Pyo, H; Lee, H; Oh, D; Noh, JM; Ahn, YC; Kim, CG; Yoon, HI; Lee, J; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ku, BM; Shin, EC; Ahn, MJ
    View PubMed
  • CANCER MED-US 2022 10.1002/cam4.5460 Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma Park, S; Cha, H; Kim, HS; Lee, B; Kim, S; Kim, TM; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Park, WY; Lee, SH
    View PubMed
  • CLIN CANCER RES 2022 10.1158/1078-0432.CCR-22-0879 Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC br Jung, HA; Lim, J; Choi, YL; Lee, SH; Joung, JG; Jeon, YJ; Choi, JW; Shin, S; Cho, JH; Kim, HK; Choi, YS; Zo, JI; Shim, YM; Park, S; Sun, JM; Ahn, JS; Ahn, MJ; Han, JH; Park, WY; Kim, J; Park, K
    View PubMed
  • PLOS ONE 2022 10.1371/journal.pone.0274830 Prognostic value of FOXP3+regulatory T cells for patients with locally advanced oropharyngeal squamous cell carcinoma Hur, JY; Ku, BM; Park, S; Jung, HA; Lee, SH; Ahn, MJ
    View PubMed
  • ISCIENCE 2022 10.1016/j.isci.2022.105358 Cellular plasticity and immune microenvironment of malignant pleural effusion are associated with EGFR-TKI resistance in non-small-cell lung carcinoma Jeong, HO; Lee, H; Kim, H; Jang, J; Kim, S; Hwang, T; Choi, DWY; Kim, HS; Lee, N; Lee, YM; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SM; Lee, SH
    View PubMed
  • CLIN CANCER RES 2022 10.1158/1078-0432.CCR-22-1238 A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11) Jung, HA; Park, KU; Cho, S; Lim, J; Lee, KW; Hong, MH; Yun, TK; An, HJ; Park, WY; Pereira, S; Ock, CY; Keam, B
    View PubMed
  • FRONT MED-LAUSANNE 2022 10.3389/fmed.2022.896494 Metabolic parameters on baseline F-18-FDG PET/CT are potential predictive biomarkers for immunotherapy in patients with head and neck squamous cell carcinoma Kwon, HR; Cho, JH; Park, S; Lee, SH; Ahn, MJ; Choi, JY; Lee, KH; Jung, HA; Moon, SH
    View PubMed
  • ONCOTARGETS THER 2022 10.2147/OTT.S362535 Sequential Afatinib and Osimertinib in Asian Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer and Acquired T790M: Combined Analysis of Two Global Non-Interventional Studies Miura, S; Jung, HA; Lee, SY; Lee, SH; Lee, MK; Lee, YC; Hochmair, MJ; Yang, CT; Marten, A; Yang, JCH; Popat, S
    View PubMed
  • J THORAC ONCOL 2022 10.1016/j.jtho.2022.04.001 Bevacizumab Plus Atezolizumab After Progression on Atezolizumab Monotherapy in Pretreated Patients With NSCLC: An Open-Label, Two-Stage, Phase 2 Trial Lee, J; Koh, J; Kim, HK; Hong, S; Kim, K; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • CANCER RES TREAT 2022 10.4143/crt.2021.1019 A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer Kim, HR; Lee, SJ; Park, S; Jung, HA; Lee, SH; Jeong, HS; Chung, MK; Ahn, MJ
    View PubMed
  • J CLIN ONCOL 2022 10.1200/JCO.21.02010 Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer Park, S; Ock, CY; Kim, H; Pereira, S; Park, S; Ma, M; Choi, S; Kim, S; Shin, S; Aum, BJ; Paeng, K; Yoo, D; Cha, H; Park, S; Suh, KJ; Jung, HA; Kim, SH; Kim, YJ; Sun, JM; Chung, JH; Ahn, JS; Ahn, MJ; Lee, JS; Park, K; Song, SY; Bang, YJ; Choi, YL; Mok, TS; Lee, SH
    View PubMed
  • CLIN CANCER RES 2022 10.1158/1078-0432.CCR-21-3646 Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study Jung, HA; Park, S; Choi, YL; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM
    View PubMed
  • INT J RADIAT ONCOL 2022 10.1016/j.ijrobp.2022.02.003 Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1 Kim, KH; Pyo, H; Lee, H; Oh, D; Noh, JM; Ahn, YC; Yoon, HI; Moon, H; Lee, J; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ku, BM; Ahn, MJ; Shin, EC
    View PubMed
  • TRANSL LUNG CANCER R 2022 10.21037/tlcr-22-79 Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small-cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22 Jung, HA; Hong, MH; Lee, HW; Lee, KH; Kim, IW; Min, YJ; Ahn, HK; Shim, BY; Choi, YH; Lee, YG; Kim, JA; Jang, JS; Shin, SH; Park, KU; Kang, JH; Park, K
    View PubMed
  • ONCOLOGIST 2022 10.1093/oncolo/oyac022 Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG) Popat, S; Hsia, TC; Hung, JY; Jung, HA; Shih, JY; Park, CK; Lee, SH; Okamoto, T; Ahn, HK; Lee, YC; Sato, Y; Lee, SS; Mascaux, C; Daoud, H; Marten, A; Miura, S
    View PubMed
  • EUR J CANCER 2022 10.1016/j.ejca.2022.03.034 Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer Park, S; Noh, JM; Choi, YL; Chi, SA; Kim, K; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM
    View PubMed
  • CANCER MED-US 2022 10.1002/cam4.4663 Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors Kwon, M; Ku, BM; Olsen, S; Park, S; Lefterova, M; Odegaard, J; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • CANCER RES TREAT 2022 10.4143/crt.2021.306 Long-term Survival in Non-Small Cell Lung Cancer Patients with Metachronous Brain-Only Oligorecurrence Who Underwent Definitive Treatment Kim, H; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • J NEURO-ONCOL 2022 10.1007/s11060-021-03930-4 Bevacizumab plus irinotecan with or without gamma knife radiosurgery after failure of concurrent chemo-radiotherapy for high-grade glioma Lee, YP; Jung, HA; Lee, MS; Choi, JW; Kong, DS; Seol, HJ; Nam, DH; Lee, JI; Lee, SH
    View PubMed
  • EUR J CANCER 2021 10.1016/j.ejca.2021.09.037 Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience Lee, YP; Jeong, BH; Eun, Y; Kang, CI; Park, S; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
    View PubMed
  • TRANSL LUNG CANCER R 2021 10.21037/tlcr-21-691 Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment Hwang, S; Hong, TH; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Choi, YL; Lee, SH
    View PubMed
  • LUNG CANCER 2021 10.1016/j.lungcan.2021.09.009 Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG) Popat, S; Jung, HA; Lee, SY; Hochmair, MJ; Lee, SH; Escriu, C; Lee, MK; Migliorino, MR; Lee, YC; Girard, N; Daoud, H; Marten, A; Miura, S
    View PubMed
  • TRANSL LUNG CANCER R 2021 10.21037/tlcr-21-531 Real-time autOmatically updated data warehOuse in healThcare (ROOT): an innovative and automated data collection system Jung, HA; Jeong, O; Chang, DK; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K
    View PubMed
  • CHEMOTHERAPY 2021 10.1159/000517245 Treatment and Outcomes of Metastatic Pancreatic Cancer in Elderly Patients Jung, HA; Han, BR; Kim, HY; Kim, HJ; Zang, DY; Jung, JY
    View PubMed
  • CANCER 2021 10.1002/cncr.33571 High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean lung liquid versus invasive biopsy program Park1, S; Olsen, S; Ku, BM; Lee, MS; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Choi, YL; Ahn, MJ
    View PubMed
  • CANCERS 2021 10.3390/cancers13081913 Prognostic Value of the Neutrophil-to-Lymphocyte Ratio before and after Radiotherapy for Anaplastic Thyroid Carcinoma Park1, J; Park, J; Shin, JH; Oh, YL; Jung, HA; Chung, MK; Choe, JH; Ahn, YC; Kim, SW; Chung, JH; Kim, TH; Noh, JM
    View PubMed
  • KOREAN J INTERN MED 2021 10.3904/kjim.2019.385 Mutations in genes affecting DNA methylation enhances responses to decitabine in patients with myelodysplastic syndrome Jung1, HA; Jung, CW; Jang, JH
    View PubMed
  • J KOREAN NEUROSURG SOC 2021 10.3340/jkns.2020.0135 Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery Lee1, MH; Cho, KR; Choi, JW; Kong, DS; Seol, HJ; Nam, DH; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Lee, JI
    View PubMed
  • TRANSL LUNG CANCER R 2021 10.21037/tlcr-20-1128 Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors Kim1, H; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
    View PubMed
  • J THORAC ONCOL 2020 10.1016/j.jtho.2020.06.018 Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status Lee1, J; Choi, YL; Han, J; Park, S; Jung, HA; Su, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • CANCER IMMUNOL IMMUN 2020 10.1007/s00262-020-02766-7 Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect Lee1, J; Kim, B; Jung, HA; Choi, YL; Sun, JM
    View PubMed
  • J IMMUNOTHER CANCER 2020 10.1136/jitc-2020-001199 Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity Hong1, TH; Cha, H; Shim, JH; Lee, B; Chung, J; Lee, C; Kim, NKD; Choi, YL; Hwang, S; Lee, Y; Park, S; Jung, HA; Kim, JY; Park, YH; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH; Park, WY
    View PubMed
  • BIOLOGY-BASEL 2020 10.3390/biology9100326 Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations Are They Different from Those with Common EGFR Mutations? Jung1, HA; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K
    View PubMed
  • CANCER RES TREAT 2020 10.4143/crt.2020.278 EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation Park1, S; Ku, BM; Jung, HA; Sun, JM; Ahn, JS; Lee, SH; Park, K; Ahn, MJ
    View PubMed
  • TRANSL LUNG CANCER R 2020 10.21037/tlcr-20-379 The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer Jung1, HA; Woo, SY; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
    View PubMed
  • CANCER 2020 10.1002/cncr.33048 Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy Park1, S; Shim, J; Mortimer, PGS; Smith, SA; Godin, RE; Hollingsworth, SJ; Kim, HJ; Jung, HA; Sun, JM; Park, WY; Ahn, JS; Ahn, MJ; Lee, SH; Park, K
    View PubMed
  • BMC CANCER 2020 10.1186/s12885-020-07214-4 Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer real-world data in Korea Kim1, H; Kwon, M; Kim, B; Jung, HA; Sun, JM; Lee, SH; Park, K; Ahn, MJ
    View PubMed
  • LUNG CANCER 2020 10.1016/j.lungcan.2020.05.033 Ten-year patient journey of stage III non-small cell lung cancer patients A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study) Jung1, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K
    View PubMed
  • LUNG CANCER 2020 10.1016/j.lungcan.2020.05.035 Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer Jung1, HA; Noh, JM; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Pyo, H; Ahn, YC; Park, K
    View PubMed
  • EXPERT OPIN PHARMACO 2020 10.1080/14656566.2020.1798932 Evaluating entrectinib as a treatment option for non-small cell lung cancer Lee1, JY; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • ANN ONCOL 2020 10.1016/j.annonc.2020.04.004 HLA-corrected tumor mutation burden and homologous recombination de fi ciency for the prediction of response to PD -(L)1 blockade in advanced non -small -cell lung cancer patients Shim1, JH; Kim, HS; Cha, H; Kim, S; Kim, TM; Anagnostou, V; Choi, YL; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Park, WY; Lee, SH
    View PubMed
  • EUR J CANCER 2020 10.1016/j.ejca.2020.03.029 Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma Lee1, J; La Choi, Y; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
    View PubMed
  • CLIN LUNG CANCER 2020 10.1016/j.cllc.2019.11.006 Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests Byeon1, S; Lee, B; Park, WY; Choi, YL; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH
    View PubMed
  • IN VIVO 2020 10.21873/invivo.11920 Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With MET Exon 14 Skipping Hur1, JY; Ku, BM; Shim, JH; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • NAT COMMUN 2020 10.1038/s41467-020-16164-1 Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma Kim1, N; Kim, HK; Lee, K; Hong, Y; Cho, JH; Choi, JW; Lee, J; Suh, YL; Ku, BM; Eum, HH; Choi, S; Choi, YL; Joung, JG; Park, WY; Jung, HA; Sun, JM; Lee, SN; Ahn, JS; Park, K; Ahn, MJ; Lee, HO
    View PubMed
  • Cancer Med 2020 10.1002/cam4.2868 PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence Byeon1, S; Cho, JH; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • BMC OPHTHALMOL 2020 10.1186/s12886-019-1285-9 Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors Shin1, E; Lim, DH; Han, JS; Nam, D; Park, K; Ahn, MJ; Kang, WK; Lee, JY; Ahn, JS; Lee, SH; Sun, JM; Jung, HA; Chung, TY
    View PubMed
  • CANCER RES TREAT 2020 10.4143/crt.2019.186 Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea Lee1, K; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahm, MJ
    View PubMed
  • Cancer Med, 2019.09, 8(12):5431-5437 Comparative effectiveness of palliative chemotherapy versus neoadjuvant chemotherapy followed by radical cystectomy versus cystectomy followed by adjuvant chemotherapy versus cystectomy for regional node-positive bladder cancer: A retrospective analysis: KCSG GU 17-03. Woo Kyun Bae1, Hyo Jin Lee, Se Hoon Park, Jung Hoon Kim, Hee Jun Kim, Chi Hoon Maeng, Inkeun Park, Byeong Seok Sohn, Jung A. Kim, Kyung Hee Lee, Do Hyoung Lim, Hyun Chang, Sung Min Kim, Ho Young Kim, Hunho Song, Seungtaek Lim, Jae Ho Byun, Hyun Ae Jung
    View PubMed
  • INT J CANCER 2019 10.1002/ijc.32235 Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease Shin1, SH; Park, HY; Im, Y; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, HY; Lee, SH
    View PubMed
  • Cancer Med 2019 10.1002/cam4.2446 Comparative effectiveness of palliative chemotherapy versus neoadjuvant chemotherapy followed by radical cystectomy versus cystectomy followed by adjuvant chemotherapy versus cystectomy for regional node-positive bladder cancer: A retrospective analysis: KCSG GU 17-03 Bae1, WK; Lee, HJ; Park, SH; Kim, JH; Kim, HJ; Maeng, CH; Park, I; Sohn, BS; Kim, JA; Lee, KH; Lim, D; Chang, H; Kim, SM; Kim, HY; Song, H; Lim, S; Byun, JH; Jung, HA
    View PubMed
  • J CANCER RES CLIN 2019 10.1007/s00432-019-02889-0 Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma Cho1, JH; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
    View PubMed
  • LUNG CANCER 2019 10.1016/j.lungcan.2019.01.012 Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer Lee1, K; Kim, Y; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Choi, YL; Sun, JM
    View PubMed
  • Ann Lab Med, 2018.05, 38(3):196-203 Clinical Utility of a Diagnostic Approach to Detect Genetic Abnormalities in Multiple Myeloma: A Single Institution Experience Hyun Ae Jung1, Mi-Ae Jang, Sun-Hee Kim, Kihyun Kim
    View PubMed
  • LUNG CANCER 2018 10.1016/j.lungcan.2018.06.009 Efficacy of mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) in patients with advanced pulmonary pleomorphic carcinoma Lee1, J; Jung, HA; Kim, Y; Choi, S; Han, J; Choi, YL; Lee, SH; Ahn, JS; Park, K; Sun, JM
    View PubMed
  • ANN LAB MED 2018 10.3343/alm.2018.38.3.196 Clinical Utility of a Diagnostic Approach to Detect Genetic Abnormalities in Multiple Myeloma: A Single Institution Experience Jung1, HA; Jang, MA; Kim, K; Kim, SH
    View PubMed
  • Tumour Biol. 2015.02, 36(2):1073-9 Prognostic relevance of biological subtype overriding TNM staging in breast cancer: discordance between stage and biology Hyun Ae Jung1, Yeon Hee Park, Moonjin Kim, Sungmin Kim, Won Jin Chang, Moon Ki Choi, Jung Yong Hong, Seok Won Kim, Won Ho Kil, Jeong Eon Lee, Seok Jin Nam, Jin Seok Ahn and Young-Hyuck Im
    View PubMed
  • Oncotarget. 2015.06.30, 6(18):16653-62. Platelet response at second cycle of decitabine can predict response and survival for myelodysplastic syndromes (MDS) patients Hyun Ae Jung1, Moonjin Kim, Sungmin Kim, Chi Hoon Maeng, Chul Won Jung, and Jun Ho Jang
    View PubMed
  • Cancer Res Treat, 2015.01, 47(1):72-7 Changes in the Mean Corpuscular Volume after Capecitabine Treatment Is Associated with Clinical Response and Survival in Patients with Advanced Gastric Cancer Hyun Ae Jung1, Hyun-Jun Kim,Chi Hoon Maeng, Se Hoon Park, Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang
    View PubMed
  • J Transl Med, 2014.10.25, 12:299 High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma Hyun Ae Jung1, Bo Mi Ku, Jong-Mu Sun, Young Hyeh Ko, Han-Sin Jeong, Young-Ik Son, Chung-Hwan Baek, Keunchil Park and Myung-Ju Ahn
    View PubMed
  • Korean J Intern Med, 2014.05, 29(3):398-401 Infective Endocarditis due to Extended Spectrum Beta-Lactamase (ESBL) producing Klebsiella Pneumonia Hyun-Ae Jung1, Young Eun Ha, Damin Kim, Jihyun Park , Cheol-In Kang , Doo Ryeon Chung ,Seung Woo Park , Ki Ik Sung , Jae-Hoon Song and Kyong Ran Peck
    View PubMed
  • Chemotherapy. 2014, 60(2):73-80 Treatment Outcome and Relevance of Palliative Chemotherapy in Urachal Cancer Hyun Ae Jung1, Jong-Mu Sun, Se Hoon Park, Ghee Young Kwon and Ho Yeong Lim
    View PubMed
  • Leuk Lymphoma. 2014.10, 55(10):2395-7 Spinal cord compression in multiple myeloma: a single center experience Hyun Ae Jung1, Soo Hee Cho, Seok Jin Kim, Jun Ho Jang, Won Seog Kim , Chul Won Jung , Kihyun Kim
    View PubMed
  • Anticancer Res, 2014.02, 34(2):1037-45 Prognostic Factor Analysis in Core-Binding Factor-positive Acute Myeloid Leukemia Hyun Ae Jung1, Chi Hoon Maeng, Silvia Park, Seok Jin Kim, Kihyun Kim, Jun Ho Jang and Chul Won Jung
    View PubMed
  • Journal of Hematology & Oncology, 2013. 11, 6:86 Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma study group Hyun Ae Jung1, Seok Jin Kim, Shih-Sung Chuang, Huangming Hong, Cheng-Cheng Guo, Junning Cao, Xiao-Nan Hong, Ritsuro Suzuki, Hye Jin Kang, Jong Ho Won, Wee-Joo Chng, Yok-Lam Kwong, Cheolwon Suh, Yu-Qin Song, Jun Zhu, Kevin Tay, Soon Thye Lim, Junji Suzumiya, Tong Yu Lin and Won Seog Kim
    View PubMed
  • Cancer Res Treat, 2013. 12, 45(4):285-94 Nomogram to Predict Treatment Outcome of Fluoropyrimidine/Platinum-Based Chemotherapy in Metastatic Esophageal Squamous Hyun Ae Jung1, Antoine Adenis, Jeeyun Lee, Se Hoon Park, Chi Hoon Maeng, Silvia Park, Hee Kyung Ahn, Young Mog Shim, Nicolas Penel, Young-Hyuck Im
    View PubMed
  • Ann Hematol, 2012.11, 91(11):1747 - 1756 Prognostic relevance of pretreatment quality of life in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: Results from a prospective cohort study Hyun Ae Jung 1, Silvia Park, Jin Hyun Cho, Seonwoo Kim ,Young Hyeh Ko ,Seok Jin Kim ,Won Seog Kim
    View PubMed

해당하는 결과가 없습니다.